Cryoport France
Cryoport France is recorded as a service provider in 9 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 9 of 9 trials · Latest update first
An open-label, phase I/II first-in-human, dose escalation and confirmation study to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic and anti-tumour activity of IPN01195 as single agent in adult participants with advanced solid tumours
Sponsor Ipsen Pharma
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T cells (CABA-201) in Subjects with Active Systemic Lupus Erythematosus
Sponsor Cabaletta Bio Inc.
- Start (EU)
- Latest update
- Estimated end
An open-label Phase 2a study to evaluate the safety and efficacy of AlloNK®, an allogeneic cord blood-derived NK cell therapy, in combination with rituximab in relapsing forms of B-cell dependent rheumatologic diseases
Sponsor Artiva Biotherapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
EORTC-2427-BTG: Vorasidenib as maintenance treatment after first-line chemoradiotherapy in IDH-mutant grade 2 or 3 astrocytoma: a placebo-controlled, triple-blind, randomized phase III study (VIGOR)
Sponsor Europese Organisatie Voor Onderzoek En Behandeling Van Kanker Organisation Europeenne Pour La Recherche Et Le Traitement Du Cancer European Organi
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T cells (CABA-201) in Subjects with Active Idiopathic Inflammatory Myopathy or Active Juvenile Idiopathic Inflammatory Myopathy
Sponsor Cabaletta Bio Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
EORTC 2022-MG: Adjuvant tebentafusp (IMCgp100) versus observation in HLA-A*02:01 positive patients following definitive treatment of high-risk uveal melanoma: an EORTC randomized phase III study (ATOM Trial)
Sponsor European Organisation For Research And Treatment Of Cancer
- Start (EU)
- Latest update
- Estimated end
An Open-Label, Phase I/II First-in-Human, Dose Escalation, Dose Optimisation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 as Single Agent in Adult Participants with Locally Advanced or Metastatic Solid Tumours.
Sponsor Ipsen Pharma
- Start (EU)
- Latest update
- Estimated end
EORTC-1809-STBSG: A randomized phase III study of neoadjuvant chemotherapy followed by surgery versus surgery alone for patients with High Risk RetroPeritoneal Sarcoma (STRASS 2)
Sponsor European Organisation For Research And Treatment Of Cancer
- Start (EU)
- Latest update
- Estimated end
Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, immunogenicity and safety of one dose of OVX836 influenza vaccine 480μg, after intramuscular administration in healthy subjects aged 18-59 years
Sponsor Osivax
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Cryoport France?
The 2026-10-09 snapshot links Cryoport France to 9 distinct CTIS trials. Recorded services include Medicinal product management, Biobanking, Biobanking, Shipment of samples, Human Biological Material management (Sample shipment), among 6 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Cryoport France?
The most frequently recorded therapeutic areas are Immunology, Rheumatology, Musculoskeletal, Solid Tumor Oncology. Recorded phases include Phase 2, Phase 1, Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Cryoport France conducted?
The linked trials record locations in 18 countries, including Spain, France, Germany, Italy, Belgium. These are trial locations, not confirmed office locations or countries where Cryoport France delivered services.
What can this page tell me about Cryoport France's trial experience?
Browse 9 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Cryoport France. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Cryoport France